STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACRV
  4. [Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Acrivon Therapeutics (ACRV) director granted 9,366 restricted stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BAUM CHARLES M reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics director Charles M. Baum received an equity grant in the form of restricted stock units. The Form 4 reports an award of 9,366 shares of Common Stock at no purchase price, increasing his directly held stake to 9,366 shares.

The footnotes explain these are RSUs, each representing a contingent right to receive one share of Common Stock. The RSUs vest in full on May 18, 2027, provided Baum remains in continuous service with the company through that vesting date.

Positive

  • None.

Negative

  • None.
Insider BAUM CHARLES M
Role null
Type Security Shares Price Value
Grant/Award Common Stock 9,366 $0.00 --
Holdings After Transaction: Common Stock — 9,366 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 9,366 shares Restricted stock unit award to director on May 18, 2026
Price per share $0.0000 per share Equity compensation grant, non-cash award
Holdings after grant 9,366 shares Total Common Stock directly held following the RSU award
Vesting date May 18, 2027 RSUs vest in full if continuous service condition is met
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
continuous service financial
"These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service..."
vest in full financial
"These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service..."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BAUM CHARLES M
(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026A(1)9,366A$09,366D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.
/s/ Adam D. Levy, Attorney-in-Fact05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Charles M. Baum?

Acrivon Therapeutics reported that director Charles M. Baum received a grant of 9,366 restricted stock units. Each RSU represents a contingent right to one share of Common Stock, awarded as equity compensation rather than an open-market purchase.

How many Acrivon Therapeutics (ACRV) shares does Charles M. Baum hold after this Form 4?

After the reported grant, Charles M. Baum directly holds 9,366 shares of Acrivon Therapeutics Common Stock. These holdings correspond to the awarded restricted stock units, which are subject to vesting conditions before they convert into freely usable shares.

What are the terms of Charles M. Baum’s RSU award from Acrivon Therapeutics (ACRV)?

The award consists of restricted stock units, each equal to one share of Common Stock. All RSUs vest in full on May 18, 2027, if Baum maintains continuous service with Acrivon Therapeutics through that vesting date, according to the footnote disclosure.

Did Charles M. Baum buy Acrivon Therapeutics (ACRV) shares on the open market?

No, the Form 4 shows a grant of restricted stock units at a price of $0.0000 per share. This indicates an equity compensation award, not an open-market purchase, with future vesting requirements rather than an immediate cash transaction.

When do Charles M. Baum’s Acrivon Therapeutics (ACRV) RSUs vest?

The RSUs vest in full on May 18, 2027. Vesting is contingent on Charles M. Baum’s continuous service with Acrivon Therapeutics through that date, meaning the award becomes deliverable as shares only if that condition is satisfied.